Randomized, controlled, open and multicenter study that analyzes the vasomotor function 8 months after use of the drug-eluting balloon (DCB) vs. drug-eluting stent (DES) in vessels ≥ 3.5 mm

Randomized, controlled, open and multicenter study that analyzes the vasomotor function 8 months after use of the drug-eluting balloon (DCB) vs. drug-eluting stent (DES) in vessels ≥ 3.5 mm

Inclusion Criteria:

Patients who meet all of the following conditions are included.

• Patients aged ≥ 18 years and;
• Patients with chronic coronary syndrome, acute coronary syndrome without ST segment elevation or acute coronary syndrome with elevation ST segment in non-culprit lesions 48 hours after the event and;
• Patients with de novo lesions in vessels ≥ 3.5 mm without calcification significant no visible thrombus and;
• Patients who have been informed of the characteristics of the study and have provided their written informed consent.

Exclusion Criteria:

Patients who meet at least one of the following conditions are excluded:

• Patients with any contraindication for the administration of acetylcholine (ACh) or nitroglycerin (NTG).
• Patients with a history of coronary vasospasm or spontaneous dissection of the coronary artery.
• Patients with significant medical, surgical or psychiatric condition that would affect the safety of the subject or influence the outcome of the study according to the doctor's opinion.
• Patients who received a combination of DES and DCB in the same vessel
• Patients with glomerular filtration rate <30 ml/min/ 1.73 m2
• Patients with body mass index >35 (may affect the evaluation qualitative diameter of the coronary artery).
• Patients with symptomatic congestive heart failure.
• Patients with significant autoimmune inflammatory conditions and patients taking immunomodulatory medications (including methotrexate, cyclosporine, steroids).
• Patients with heart transplant.
• Patients with anemia (Hb <12 g/dL in men and <10 g/dL in women).
• Patients, women of childbearing age with a positive pregnancy test.
• Pregnant female patients.
• Patients included in other clinical trials with active follow-up.